» Articles » PMID: 2515189

Decrease in a Constitutive Form of Cytochrome P-450 by Macrolide Antibiotics

Overview
Date 1989 Oct 1
PMID 2515189
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of administration of macrolide antibiotics on cytochrome P-450 in liver microsomes of male rats were investigated. The macrolides tested were those with a 14-membered ring such as oleandomycin, troleandomycin, erythromycin and erythromycin estolate, and those with a 16-membered ring such as rokitamycin, leucomycin and josamycin. Cytochrome P-450-metabolite complex was detected with oleandomycin, troleandomycin, erythromycin and erythromycin estolate, whereas no such effect was observed with rokitamycin, leucomycin and josamycin. The content of uncomplexed cytochrome P-450 in liver microsomes remained unchanged with rokitamycin, leucomycin and josamycin, decreased with troleandomycin and oleandomycin, and increased with erythromycin and erythromycin estolate, indicating that oleandomycin, troleandomycin, erythromycin and erythromycin estolate also affect the amounts of other forms of cytochrome P-450. The administration of oleandomycin, troleandomycin, erythromycin and erythromycin estolate resulted in a dramatic decrease in the activities of testosterone 2 alpha- and 16 alpha-hydroxylases in liver microsomes. Supporting these results, a marked decrease (more than 75%) in the content of P-450-male, a major constitutive form of cytochrome P-450 in male rats, was noted with oleandomycin, troleandomycin, erythromycin and erythromycin estolate, while the decrease was rather small with rokitamycin and leucomycin. We conclude that the administration of the 14-membered ring macrolides may affect drug and steroid metabolism not only by formation of P-450-metabolite complex but also by decrease in the content of P-450-male.

Citing Articles

Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

Zhou S, Chan E, Li X, Huang M Ther Clin Risk Manag. 2008; 1(1):3-13.

PMID: 18360537 PMC: 1661603. DOI: 10.2147/tcrm.1.1.3.53600.


Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Zhou S, Chan S, Goh B, Chan E, Duan W, Huang M Clin Pharmacokinet. 2005; 44(3):279-304.

PMID: 15762770 DOI: 10.2165/00003088-200544030-00005.


Adverse effects of macrolide antibacterials.

PERITI P, Mazzei T, Mini E, Novelli A Drug Saf. 1993; 9(5):346-64.

PMID: 8280403 DOI: 10.2165/00002018-199309050-00004.


Macrolide antibacterials. Drug interactions of clinical significance.

von Rosensteil N, Adam D Drug Saf. 1995; 13(2):105-22.

PMID: 7576262 DOI: 10.2165/00002018-199513020-00005.


Pharmacokinetic drug interactions of macrolides.

PERITI P, Mazzei T, Mini E, Novelli A Clin Pharmacokinet. 1992; 23(2):106-31.

PMID: 1511528 DOI: 10.2165/00003088-199223020-00004.